PURPOSE: To investigate the incidence and prognosis of severe radiation-induced lymphopenia (sRIL) after postoperative radiotherapy (PORT) for resected NSCLC. PATIENTS AND METHODS: Between 1998 and 2017, 170 patients treated with PORT for NSCLC were retrospectively reviewed. Lymphopenia was divided into tertiles with severe lymphopenia defined as absolute lymphocyte counts (ALC) < 0.37 × 103/ul. RESULTS: sRIL was observed in 32.3% of patients. Multivariable logistic regression analysis indicated sRIL was associated with planning target volume radiation fraction numbers (OR 1.09, p = 0.005) and total lung mean dose (OR 1.12, p = 0.006). With a median follow-up time of 12.2 years, the median progression-free survival and overall survival were 14.8 months and 28.4 months respectively in patients with sRIL, vs. 21.7 months (p = 0.008) and 48.3 months (p = 0.01) respectively in patients without sRIL. Multivariable analyses indicated sRIL significantly decreased OS (HR 1.95, p < 0.01). Since PORT for stage I-II NSCLC was done largely for positive margins, which may confound the contribution of severe RIL, we analyzed stage III separately and found that sRIL also significantly decreased OS (HR 1.88, p = 0.004) in multivariable analysis. CONCLUSION: For this long-term outcome study, severe RIL correlated with total lung mean dose and radiation fractionation numbers, and was a strong prognostic factor for poor survival in PORT patients, particularly in patients with stage III NSCLC, highlighting the importance of an intact immune system for post-radiation immunologic disease surveillance.
PURPOSE: To investigate the incidence and prognosis of severe radiation-induced lymphopenia (sRIL) after postoperative radiotherapy (PORT) for resected NSCLC. PATIENTS AND METHODS: Between 1998 and 2017, 170 patients treated with PORT for NSCLC were retrospectively reviewed. Lymphopenia was divided into tertiles with severe lymphopenia defined as absolute lymphocyte counts (ALC) < 0.37 × 103/ul. RESULTS: sRIL was observed in 32.3% of patients. Multivariable logistic regression analysis indicated sRIL was associated with planning target volume radiation fraction numbers (OR 1.09, p = 0.005) and total lung mean dose (OR 1.12, p = 0.006). With a median follow-up time of 12.2 years, the median progression-free survival and overall survival were 14.8 months and 28.4 months respectively in patients with sRIL, vs. 21.7 months (p = 0.008) and 48.3 months (p = 0.01) respectively in patients without sRIL. Multivariable analyses indicated sRIL significantly decreased OS (HR 1.95, p < 0.01). Since PORT for stage I-II NSCLC was done largely for positive margins, which may confound the contribution of severe RIL, we analyzed stage III separately and found that sRIL also significantly decreased OS (HR 1.88, p = 0.004) in multivariable analysis. CONCLUSION: For this long-term outcome study, severe RIL correlated with total lung mean dose and radiation fractionation numbers, and was a strong prognostic factor for poor survival in PORT patients, particularly in patients with stage III NSCLC, highlighting the importance of an intact immune system for post-radiation immunologic disease surveillance.
Authors: Peter S N van Rossum; Wei Deng; David M Routman; Amy Y Liu; Cai Xu; Yutaka Shiraishi; Max Peters; Kenneth W Merrell; Christopher L Hallemeier; Radhe Mohan; Steven H Lin Journal: Pract Radiat Oncol Date: 2019-07-29
Authors: Colton J Ladbury; Chad G Rusthoven; D Ross Camidge; Brian D Kavanagh; Sameer K Nath Journal: Int J Radiat Oncol Biol Phys Date: 2019-06-05 Impact factor: 7.038
Authors: Chad Tang; Zhongxing Liao; Daniel Gomez; Lawrence Levy; Yan Zhuang; Rediet A Gebremichael; David S Hong; Ritsuko Komaki; James W Welsh Journal: Int J Radiat Oncol Biol Phys Date: 2014-07-08 Impact factor: 7.038
Authors: Yutaka Shiraishi; Penny Fang; Cai Xu; Juhee Song; Sunil Krishnan; Eugene J Koay; Reza J Mehran; Wayne L Hofstetter; Mariela Blum-Murphy; Jaffer A Ajani; Ritsuko Komaki; Bruce Minsky; Radhe Mohan; Charles C Hsu; Brian P Hobbs; Steven H Lin Journal: Radiother Oncol Date: 2017-12-14 Impact factor: 6.280
Authors: Luke R G Pike; Andrew Bang; Brandon A Mahal; Allison Taylor; Monica Krishnan; Alexander Spektor; Daniel N Cagney; Ayal A Aizer; Brian M Alexander; Osama Rahma; Tracy Balboni; Patrick A Ott; F Stephen Hodi; Jonathan D Schoenfeld Journal: Int J Radiat Oncol Biol Phys Date: 2018-09-15 Impact factor: 7.038
Authors: Wang Jing; Ting Xu; Lirong Wu; Pablo B Lopez; Clemens Grassberger; Susannah G Ellsworth; Radhe Mohan; Brian P Hobbs; George R Blumenschein; Janet Tu; Mehmet Altan; Percy Lee; Zhongxing Liao; Steven H Lin Journal: JTO Clin Res Rep Date: 2022-08-07